FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk
Executive Summary
Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.
You may also be interested in...
Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says
US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.
Keytruda's New Tissue-Agnostic Indication Could Prompt Orphan Policy Changes
US FDA contemplating how to match orphan designation process with drug development moving to molecularly-targeted therapies.
Azurity’s Xatmep Promotional Email To Healthcare Professionals Gets Dinged By US FDA
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.
Need a specific report? 1000+ reports available
Buy Reports